Renal clearable nanocarriers: Overcoming the physiological barriers for precise drug delivery and clearance.,Journal of Controlled Release

当前位置： X-MOL 学术 › J. Control. Release › 论文详情

Our official English website, www.x-mol.net, welcomes your feedback! (Note: you will need to create a separate account there.)

Renal clearable nanocarriers: Overcoming the physiological barriers for precise drug delivery and clearance.
Journal of Controlled Release ( IF 10.5 ) Pub Date : 2020-03-16 , DOI: 10.1016/j.jconrel.2020.03.020
Chuanqi Peng ₁ , Yingyu Huang ₁ , Jie Zheng ₁

Affiliation

Physiological barriers encountered in the clinical translation of cancer nanomedicines inspire the community to more deeply understand nano-bio interactions in not only tumor microenvironment but also entire body and develop new nanocarriers to tackle these barriers. Renal clearable nanocarriers are one kind of these newly emerged drug delivery systems (DDSs), which enable drugs to rapidly penetrate into the tumor cores with no need of long blood retention and escape macrophage uptake in the meantime they can also enhance body elimination of non-targeted anticancer drugs. As a result, they can improve therapeutic efficacies and reduce side effects of anticancer drugs. Not limited to anticancer drugs, diagnostic agents can also be achieved with these renal clearable DDSs, which might also be applied to improve the precision in the gene editing and immunotherapy in the future.

中文翻译：

肾脏可清除的纳米载体：克服生理障碍，实现精确的药物输送和清除。

癌症纳米药物临床转化中遇到的生理障碍激发了人们更深入地了解肿瘤微环境和整个身体中的纳米生物相互作用，并开发新的纳米载体来克服这些障碍。肾脏可清除的纳米载体是这些新兴药物递送系统（DDS）中的一种，它使药物能够快速渗透到肿瘤核心，无需长时间的血液保留并逃避巨噬细胞的摄取，同时它们还可以增强体内非物质的消除。靶向抗癌药物。因此，它们可以提高治疗效果并减少抗癌药物的副作用。不仅限于抗癌药物，这些肾脏可清除的DDS还可以实现诊断试剂，这也可能用于提高未来基因编辑和免疫治疗的精度。

更新日期：2020-04-21

点击分享查看原文

点击收藏

阅读更多本刊最新论文本刊介绍/投稿指南11